Future developments in myeloma treatment

Sally Moore, MD, Royal United Hospital, Bath, UK, briefly discusses future developments in multiple myeloma (MM) treatment, drawing focus on the use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. Dr Moore also mentions the excitement surrounding other novel agents in myeloma treatment, their increasing efficacy, and the improved management of toxicities. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.